Blog

Showard Law Tucson Injury Firm | toll free 866-307-2147 or 520-622-3344

Pfizer Recalls 1M Packets of Birth Control Pills

As the result of a packaging error, Pfizer has recalled 1M packets of birth control pills.  A statement issued by Pfizer indicated that, “As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception and at risk for unintended pregnancy.  The recall involves 14 lots of Lo/Ovral-28 …

Read More

Diabetes drugs linked to pancreatic cancer- Older drug the best

Newer isn’t always better.  A new study links the drug metformin, prescribed for diabetes, to fewer cases of pancreatic cancer, at least in women, but finds other diabetes medications are associated with a higher risk of the disease. According to Dr. Peter Butler, a diabetes researcher at UCLA  ”the oldest drug we have for diabetes, metformin, is undoubtedly the best …

Read More

Accidental Child Poisoning: A growing Epidemic

  The Journal of Pediatrics recently published a study showing thtat over the past decade increasing numbers of young children have been hospitalized or injured due to accidental poisoning from prescription and over-the-counter (OTC) medications.  The majority of the cases involved unintentional self-ingestion for example where a child finds pills from an open container prescrived to a bparent or family …

Read More

CAUTION: FDA Warns of Opioid Mix-Up

The FDA has issued a warning that Percocet and eight other opiod products packaged by Novartis may have been mixed up. Patients should be wary of any pills that are different in size, shape, color or markings from their standard medication. A full list of the effected medications can be viewed on the FDA website at: http://www.fda.gov/Drugs/DrugSafety/ucm286226.htm

Read More

Surgical Mesh Makers ordered by FDA to Study Risks

The Food and Drug Administration has ordered medical device manufacturers to study safety complications with surgical mesh used in women’s pelvic surgeries. In April an FDA report found that women who have the surgical mesh implanted are at greater risk of pain , bleeding and infection than women who have traditional surgery with stitches. For more information visit the FDA …

Read More

BREAKING NEWS- YAZ Settlement Discussions to Begin

January 5, 2012.  The first Yaz trial which was set to begin next week has been postponed in an effort to reach a settlement of the claims. Judge David Herndon has appointed a mediator to work with the parties to reach a settlement. There have been more than 10,000 suites filed in the Multidistrict Litigation.

Read More

ACTOS MDL Established

On December 29, 2011 the Judicial Panel on Multidistrict Litigation (JPML) established MDL No. 2299 for all federal claims alleging injury caused by the diabetes drug Actos.  Actos, manufactured by Takeda Pharmaceuticals America Inc., is the tenth best-selling medication in the U.S. and has been found to increase the risk of developing bladder cancer in patients who have taken  Actos …

Read More

Newer Implants Not Better, Many Worse

Over 700,000 hip and knee replacements are performed each year in the United States. As the population ages this number will increase significantly. There is concern that newer implants are being approved with insufficient testing resulting in increased failure rates. A recent study published in the Journal of Bone and Joint surgery indicates that not a single new artificial hip …

Read More

Warning renewed for Baby Acetaminophen

 The FDA has renewed a warning about the potential for dosing errors with liquid acetaminophen products for infants. FDA advisory committees made recommendations in 2009 that all liquid acetaminophen be produced in a single concentration: 160mg/5mL. The recommendation was voluntary and not all manufacturers have followed it so there are still products with strengths of 80/mL and 80mg/0.8mL in stores …

Read More

Multaq Use Limited by FDA

A recent study showed Multaq doubled the risk of heart-related complications in patients with permanent atrial fibrillation. The study, conducted bythe drugmaker,  Sanofi, showed higher rates of heart attack, stroke and death in certain patients. While the FDA did not remove Multaq from the market, they recommended restricting the use of the drug to patients with the short term form …

Read More

Page 1 of 212»

We are here to help. Please fill out the form above for a free case review.